Gottlieb rebukes Nostrum’s 300% price hike for generic antibiotic

A price hike of more than 300% by Nostrum Pharmaceuticals LLC (New Brunswick, N.J.) for a 65-year-old antibiotic met swift condemnation by FDA Commissioner Scott Gottlieb on Tuesday.

Gottlieb

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE